It is a bispecific antibody with the IgG1 isotype utilizing IMC-001 (anti-PD-L1) and IMC-002 (anti-CD47) as parent antibodies.

It binds to two antigens—PD-L1 and CD47—which are expressed on the surface of cancer cells. This action disrupts the PD-1/PD-L1 and CD47/SIRPα interactions, thereby activating both the innate and adaptive immune systems.

It selectively binds to cancer cells, providing a superior safety profile. Compared to a combination of its parent antibodies,IMC-001 and IMC-002, it demonstrates enhanced immune-activating capabilities.